China Pharma Holdings (CPHI) Land & Improvements (2014 - 2023)
China Pharma Holdings' (CPHI) quarterly Land & Improvements came in at $389808.0 in Q2 2023, down 7.12% YoY from $419685.0 in Q2 2022, and down 4.9% on a QoQ basis from $409895.0 in Q1 2023.
China Pharma Holdings (CPHI) Land & Improvements (2014 - 2023) Analysis & Trends
China Pharma Holdings (CPHI) has 10 years of Land & Improvements data on file, last reported at $389808.0 in Q2 2023.
- Quarterly Land & Improvements fell 7.12% year-over-year to $389808.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $389808.0 (down 7.12% YoY) and the FY2022 annual result came in at $404427.0, down 8.46% from the prior year.
- Land & Improvements slipped to $389808.0 in Q2 2023, from $409895.0 in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $443697.0 in Q1 2022 to a low of $389808.0 in Q2 2023.
- A 5-year average of $416443.1 and a median of $413603.0 in 2020 frame the typical range for Land & Improvements.
- Annual changes were most pronounced in 2021 — Land & Improvements advanced 9.59% — and 2022, when it declined 8.65%.
- Tracing CPHI's Land & Improvements over 5 years: stood at $403755.0 in 2019, then rose by 6.92% to $431681.0 in 2020, then gained by 2.34% to $441783.0 in 2021, then declined by 8.46% to $404427.0 in 2022, then decreased by 3.61% to $389808.0 in 2023.
- The last three Land & Improvements figures came in at $389808.0 (Q2 2023), $409895.0 (Q1 2023), and $404427.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 389,808.00 |
| Mar 31, 2023 | 409,895.00 |
| Dec 31, 2022 | 404,427.00 |
| Sep 30, 2022 | 396,726.00 |
| Jun 30, 2022 | 419,685.00 |
| Mar 31, 2022 | 443,697.00 |
| Dec 31, 2021 | 441,783.00 |
| Sep 30, 2021 | 434,310.00 |
| Jun 30, 2021 | 436,011.00 |
| Dec 31, 2020 | 431,681.00 |
| Sep 30, 2020 | 413,603.00 |
| Jun 30, 2020 | 397,864.00 |
| Mar 31, 2020 | 428,633.00 |
| Dec 31, 2019 | 403,755.00 |
| Sep 30, 2019 | 398,235.00 |
| Jun 30, 2019 | 409,716.00 |
| Mar 31, 2019 | 419,703.00 |
| Dec 31, 2018 | 409,612.00 |
| Sep 30, 2018 | 410,203.00 |
| Jun 30, 2018 | 425,541.00 |